These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10298533)

  • 1. Application of Jackson, Aspden Acute Myeloid Leukaemia model.
    Jackson RR; Birkhead BG; Bell R; Lister TA; Gregory WM
    J Oper Res Soc; 1982 Mar; 33(3):211-6. PubMed ID: 10298533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability and consistency of bone marrow assessments of complete remission in acute myelogenous leukaemia.
    Birkhead BG; Salt D; Jackson RR
    Hematol Oncol; 1987; 5(2):139-45. PubMed ID: 3474204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for acute myelogenous leukaemia.
    Powles RL; Crowther D; Bateman CJ; Beard ME; McElwain TJ; Russell J; Lister TA; Whitehouse JM; Wrigley PF; Pike M; Alexander P; Fairley GH
    Br J Cancer; 1973 Nov; 28(5):365-76. PubMed ID: 4271320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for acute myelogenous leukaemia.
    Harris R; Zuhrie SR
    Lancet; 1977 Dec; 2(8050):1228. PubMed ID: 73925
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of adult acute myelogenous leukaemia.
    Crowther D; Powles RL; Bateman CJ; Beard ME; Gauci CL; Wrigley PF; Malpas JS; Fairley GH; Scott RB
    Br Med J; 1973 Jan; 1(5846):131-7. PubMed ID: 4513355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for acute myelogenous leukemia.
    Powles RL; Lister TA; Crowther D; McElwain T; Alexander P; Fairley GH
    Bibl Haematol; 1975; (40):737-49. PubMed ID: 1057948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term remission in acute myelogenous leukaemia.
    Büchner T; Urbanitz D; Emmerich B; Fischer J; Heinecke A; Hiddemann W; Pfreundschuh M; Rühl H; Wendt F
    Lancet; 1984 Mar; 1(8376):571. PubMed ID: 6142291
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotherapy of acute myeloid leukaemia. Medical Research Council.
    Br J Cancer; 1978 Jan; 37(1):1-14. PubMed ID: 339940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes.
    Lobo PJ; Powles RL; Hanrahan A; Reynold DK
    BMJ; 1991 Feb; 302(6772):323-6. PubMed ID: 1900453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period.
    Davis CL; Rohatiner AZ; Lim J; Whelan JS; Oza AM; Amess J; Love S; Stead E; Lister TA
    Br J Haematol; 1993 Mar; 83(3):404-11. PubMed ID: 7683485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoplastic acute myelogenous leukaemia.
    Beard ME; Bateman CJ; Crowther DC; Wrigley PF; Whitehouse JM; Fairley GH; Scott RB
    Br J Haematol; 1975 Oct; 31(2):167-76. PubMed ID: 1059476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
    Versluis J; Hazenberg CL; Passweg JR; van Putten WL; Maertens J; Biemond BJ; Theobald M; Graux C; Kuball J; Schouten HC; Pabst T; Löwenberg B; Ossenkoppele G; Vellenga E; Cornelissen JJ;
    Lancet Haematol; 2015 Oct; 2(10):e427-36. PubMed ID: 26686044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy and immunotherapy interspersion: clinical studies in acute myeloblastic leukaemia.
    Whittaker JA
    Recent Results Cancer Res; 1977; (62):90-4. PubMed ID: 341252
    [No Abstract]   [Full Text] [Related]  

  • 15. Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.
    Harris R; Zuhrie SR; Freeman CB; Taylor GM; MacIver JE; Geary CG; Delamore IW; Hull PJ; Tooth JA
    Br J Cancer; 1978 Feb; 37(2):282-8. PubMed ID: 272913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient.
    Powles RL; Russell J; Lister TA; Oliver T; Whitehouse JM; Malpas J; Chapuis B; Crowther D; Alexander P
    Br J Cancer; 1977 Mar; 35(3):265-72. PubMed ID: 322689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytosine arabinoside in the management of recurrent leukaemia.
    Ganesan TS; Barnett MJ; Amos RJ; Piall EM; Aherne GW; Man A; Lister TA
    Hematol Oncol; 1987; 5(1):65-9. PubMed ID: 3471699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of remission in acute myelogenous leukaemia by a mixture of B.C.G. and irradiated leukaemia cells.
    Powles RL; Russell JA; Selby PJ; Prentice HG; Jones DR; McElwain TJ; Alexander P
    Lancet; 1977 Nov; 2(8048):1107-10. PubMed ID: 73013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute myeloid leukaemia according to the Hammersmith protocol: preliminary report.
    Paolino W; Resegotti L; Rossi M; Infelise V
    Br Med J; 1973 Sep; 3(5880):567-8. PubMed ID: 4516626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active immunotherapy trials on acute lymphoid leukemia lymphosarcoma and acute myeloid leukemia.
    Mathe G; Schwarzenberg L; Delgado M; De Vassal F
    Eur J Cancer (1965); 1977; 13(4-5):445-55. PubMed ID: 326558
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.